Healthcare

Synapticure

Website

Personalized virtual clinical care is finally here for neurodegenerative diseases like Alzheimer's and related Dementias (Cognitive), Parkinson's and Huntington's (Movement), and ALS (Motor neuron). We provide a novel approach to care in these diseases, centering a patient and caregiver around a coordinator who quarterbacks patients through our

Founded 2019Origin source ↗Checked 2026-09-15

Overview

Personalized virtual clinical care is finally here for neurodegenerative diseases like Alzheimer's and related Dementias (Cognitive), Parkinson's and Huntington's (Movement), and ALS (Motor neuron).

We provide a novel approach to care in these diseases, centering a patient and caregiver around a coordinator who quarterbacks patients through our full Multi-Disciplinary Care Resources to local aid, PT/OT and home health support. When you leave our clinic, it's not with a handful of paper referrals, but with our coordinators helping you book and find the best physicians, DME, trials, and even cheapest prescriptions. We are devoted to helping patients, from guidance on care and insurance to providing the full spectrum of investigational and clinical testing to improve outcomes.

Synapticure was built by leading patient and caregiver advocates alongside leading clinicians, biotech executives and telemedicine executives to bring the neurodegenerative disease care and treatment experience into the 21st century, and is backed by the leading Venture funds and investors in the remote health and life sciences space.

Company description As recorded 2026-11-08
About
HealthcareIndustry softwareConsumersConsumerServices

Founders & team

Previously SynaptiCure Inc., SynaptiCure

Company history As recorded 2026-11-08

Peter Wallach

Founding CEO, Founder

Founder / Founding CEO, SynaptiCure Inc. Eternal optimist. Recovering Bain consultant and avid baseball fan.

LinkedIn X
Founder profile As recorded 2026-09-15

Brian Wallach

Founder

Brian Wallach is an attorney and ALS patient. In the aftermath of his diagnosis in November 2017, he and his wife founded I AM ALS, a patient-led, patient-centric movement to lead the fight for a cure to the disease. Wallach is also an associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP. From 2014 to 2018, he served as an assistant United States attorney in the Northern District of Illinois. From 2011 to 2013, he was senior vetting counsel in the Obama White House.

LinkedIn X
Founder profile As recorded 2026-09-15

Martina de Majo

Founder

Martina is the director of research and development at Synapticure and she focuses on creating iPSC derived in vitro models to study neurodegenerative disorders. Martina received an undergraduate degree in biotechnology and a Master's degree in pharmaceutical biotechnology from the University of Rome "La Sapienza" (Italy), she then earned a PhD in clinical neuroscience from King's College London (UK) and deepened her knowledge of iPSC derived modelling in her postdoc at UCSF (US)

LinkedIn X
Founder profile As recorded 2026-09-15
115team members reported
Source-reported As recorded 2026-09-15

Founded 2019 · Source

News & product activity

Sources & observations

Y Combinator

Profile depthverified profile
Website observationwebsite reachable
Last website check2026-11-11
Location · source statedChicago, IL, USA; Remote
Pricing evidenceNo pricing page confirmed
Maturity: Not assessed · 3 of 6 areas documented

Source-based assessment · automated evidence rules

The retained text does not establish product availability or customer use.

Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.

Stage definitions
independent websitesource corroborationreachable websitedescriptive evidenceclassified market and modelsourced peoplesourced founding year
startup.observe Directory coverage · Sources & method